celgene is one of the leaders of the italian far right party the northern league he said that he wants to put an end to the arrival of refugees in italy once and for all but there is growing resistance amongst italians to his hardline immigration policy here at the baobab camp in rome volunteers provide refugees with basic services via telling authorities have continually tried to clear the camp but the volunteers continue to return and rebuild. the microns continue to come in and this long as the migrants come i hope that this part of the city and the country will do that best to welcome them but with a call good legal marriage will still fight a camp about the bab isn't alone in its resistance to hardline immigration policies . this is bent to me earlier on the italian french border more than three thousand people from italy france and spain marched against italy's and the e.u. is migration policies. what should one think about all this there's only one word for this sort of politics fascist there's nothing else to say. he said you know it up is in question i mean definitely does be

. >> i agree celgene.een appropriately rewarded i'll be buying it. >> fitg, fifth third, buying 32 calls in september i'm trying to buy those. >> i agree with celgene. i own the stock. we have gilead today the industrials are very exciting they are rolling up. making money this is something that i think continues. the industrials have more upside >> amazon after the bell >> that's going to be big. >> excited about that >> yeah. >> thinking about buying it. >> it's important. yes. >> you on track for its worst day ever >>> you bet we are michelle caruso-cabrera. facebook face plant. social media giant getting crushed on facebook's worst day ever how did the analysts miss this disaster why isn't it having a bigger effect on the overall market at these levels is it time to buy? >>> plus the treasury secretary telling cnbc this morning that the president is working to resolve a lot of trade issues. could the trade wars end before they ever get started. >> ceo of american airlines will join us shares are up des

be incredibly buttish, but i do think it's a washdown stock and ready to rally next up, how about celgeneen punished mercilessly worried about competition for the main drug as well as concerns about the pipeline and acquisition that cost too much that isn't giving the bang for the buck so far. the stock down 20% year to date. but just like gilead, it's starting to pick up its head look at that take a look at the money flow. that's the cmf down at the bottom after spending ages in negative territory, the money flow has turned green meaning the big institutional buyers are finally stepping in meanwhile, celgene seems to have made a w-shaped, and that's this, a w havana shaped bottom here granted, that is one weird looking w. but a w nonetheless. that's a bullish sign, weapon stock now breaking out where does lange see it going? he thinks it could move to the 200 day moving average look how high that would be, right? currently around 97 bucks. it says a lot in the coming ways and he may be right given the recent rotation without the rotation, though, i'm less sanguine finely, check out ilmn

i think that celgene is part of an overall group movement. rod in pennsylvania?er: good morning -- or good afternoon, rather ron from mount vessel, pennsylvania boo-yah. an hour away from your eagles. bb and c a merger with a few smaller banks. >> i like the regional banks thank heavens, pnc reports friday that determines how bb & t goes. that will be the conclusion of the "lightning round." >> the "lightning round" is sponsored by td ameritrade coach. really helped me up my game. i had a coach. math. ooh. so, why don't traders have coaches? who says they don't? coach mcadoo! you know, at td ameritrade, we offer free access to coaches and a full education curriculum- just to help you improve your skills. boom! mad skills. education to take your trading to the next level. only with td ameritrade. >>> this market keeps doing the impossible, or at least the supposedly impossible. for example we have incredibly strong job growth, yet the drug stocks, the health cares and utilities have all been excellent performers now that's not supposed to happen these interest slo

. >> celgene had a breast cancer trial that came through.t's way too cheap right now. >> surat, what have you got for me >> i'd buy delta american had earnings today. >> airlines are getting crushed today. >> company earnings are tomorrow. >> josh brown. >> i had some people ask me for a follow-up on stitch fix now that it's broken out this is a new high, higher than the ipo price. i think ifyou're trading it short term you really want to look at something like a ten-day ema and decide how much risk you want to take in the name i am still long and have no plans to sell it. >> farmer jim. >> pety was optimistic on activision, i'm optimistic on ea >> thanks, everybody "power" starts now. >> i'm tyler mathisen, welcome everybody. a trump nato trifecta. first at nato, the president slamming allies, especially germany, on everything from trade to energy. is he right to say that germany is being held captive by russia? >>> next, the president targeting china, announcing $200 billion more in tariffs with the world's second largest economy china say

the fourth big biotech to report earnings, and rounding out a very solid quarter for these amgen, celgene, and biogen and gilead its quarter actually looked very good and something that michael yee from jefferies noted for us. >> meg, thanks pf meg terrell. what do you do, guy? >> it was at 201 or so and we're basically up against it now. that's, i guess, the good news and this is the way i look at it they beat the quarter and this is the second quarter they beat by 28 cents and they raised the lower end of guidance by 50 and that's great and they lowered it by basically 28 sepps and take it for when it's forth valuation is up where amgen and you see it down in the same amount of time we're at the top end of the rage if you've been in this for a couple of months you absolutely have to take the top >> i wouldn't be surprised to see it's all in the news scenario tomorrow morning and it will be interesting to see how it reacts tomorrow a lot of the big-cap name his a run-up into earnings and it's a news, vent we'll see. >>> still ahead, check out shares of amazon up around 3% and pepsi in af

i understand why i think they have a great pipeline right now i'm in celgene >>> walter wants to talkwhat do you think, buy at these levels the heart of the trade stuff, stock has done virtually nothing. >> i'm of two minds on boeing. and i've got a lot of minds, actually but boeing is two minds. look, here is the story. you're towards the end of the cycle. however, given where oil prices have gone, there's the need for more efficient planes, which will axccelerate buying of new airplane it's a duopoly they're right in the crosshairs of a trade war but it's still a duopoly. the next trade flare up, i like the acquisition they made, more firmly in the mid and small-range jets it's going with great management, great company. i wouldn't be a seller. >> good stuff, guys. reminder, please send your questions to us at cnbc.com/half time or tweet us at halftime report use the #askhalftime keep them coming we love this interaction with all of you final trade, straight ahead teth qckreak - i love my grandma. - anncr: as you grow older, your brain naturally begins to change which may cause trou

celge celgene. >> josh brown. >> yeah, so we don't make changes based on a calendar. one thing i'll say is we remain overweight international international equities are doing worse this year than ugs they did better last year. that push >> we did not flee from those expected yields because i just don't see that as being the right behavior given where we are in the cycle >> let's get to some second half ideas, how to position your portfolio for the second half of the year we're joined by amare prize financial services advisor gale reed she's one of the barron's top 100 financial advisors on the list there hey, gale. good to have you here. >> thej overall we still broadly liked technology but we stayed balanced in most of our portfolios with a good position for taxable accounts and municipal bonds. >> international just like josh brown was saying is that a valuation call, and you say 15%, where is it historically, or where has it been >> it's been a low as 8% to 10% for an average portfolio, so we've increased slightly, and it is because of valuations, yes. >> you're un

just look at celgene it's been put through the meat grinder because of upcoming patent issues with itsr one drug remember, years ago allergan was supposed to be sold to pfizer at much higher levels that fell apart. this stock has been one disappointment after another for years. i don't want you to get your hopes up i like him a ton, pulling him. but the show is about making money, not about making friends. bottom line, the charlotte interpreted by tim collins suggests that allergan may be ready to roar here i think the fundamentals tell you to be a little bit skeptical. to me they're sayingyou need t be careful with this kind of challenge pharmaceutical company. but i accept that allergan stock was overe overly punished and continued to rally in the absence of any new negatives stick with cramer. with the new chase ink business unlimited card i get unlimited 1.5% cash back. it's so simple, i don't even have to think about it. so i think about mouthfeel. introducing chase ink business unlimited with unlimited 1.5% cash back on every purchase. the smoother the skin, the more comfortable

senate in new jersey and former ceo of celgene pharmaceuticals. you here tonight. let's take a look at -- we looked in the tease at your ad against bob menendez. but let's look at what he is running against you. >> when the cause is just, we don't give in. when the odds are long, we don't give up. >> always made us proud. always. >> we cannot let the dark cloud cast by the president define us as a country. >> martha: doesn't mention you a whole lot in there. but what you make of the race you are up against? >> i think long shot is the wrong characterization. the two most recent polls are within the margin of error. it's a dead heat right now. the people of new jersey are realizing they have a real choice this year. >> martha: you are a former marine. you were the first to go to college and your family. i think a lot of people look at you and say he's a wealthy man, very successful. you put $15 million of your own money into this race so i can imagine in a debate environment, because i moderate a lot of debates, that that's how he's going to go at

after that from nash vertex is a dop o top idea bill big gems on the siftic fibrosis and 13 played is celgene up a good quarter and that could move up 10, 15% by the end of the year. >> anything about the investing environment in general that you think favors biotechs whether it be investor tensions technology at large i mean are generalists getting back into the sector >> yeah, i think the key is that while people are i thinking a lot with drug pricing and how it's been bad for biotech stocks, i would point out the fact that the ibb index has base che hit an all-time high and that's basically because a lot of the mid-cap biotech stocks other than the big five have all done phenomenally g net gene therapy stocks. you've had a couple of m. and a acquisitions in the past i would just remind people that the good news is that generalist investors are putting money to work there has been an appear at this time for smaller and mid-cap stocks and that's where all the innovation is. and those stocks have done phenomenally well all is not bad in the biotech sector we have been directing people to may

one that could be in the crosshairs if he does is celgene who raised on two of their medicines this week. >>> pfizer announcing a plan to split into three units what's behind that and how would that work? >> well, pfizer has been operating as two units up until now. its innovative medicines on one side and essential or older drugs on another the reason for that is it was considering a split-up of the company. more recently the major consideration has been what to do with its consumer health unit which has been split into its own entity the company has been evaluating strategic options for that consumer health business since late last year and has since set it hasn't received high enough offers to consider a sale of that business. that come prices advil and chapstick and is thought to be worth $15 billion and a sale is still potentially on the table pfizer said it's still evaluating strategic alternatives for that unit and expects to make a decision this year. >> ian reed made it clear that they are delaying these price increases while they wait for the president's blueprint for bringing